Summary:
In patients with type 2 diabetes, once-weekly subcutaneous semaglutide significantly improved lipid subfraction profiles, glycemic control, and reduced body weight compared to once-daily oral sitagliptin, though it was associated with mild gastrointestinal side effects.
| PICO | Description |
|---|---|
| Population | Adults with type 2 diabetes inadequately controlled (HbA1c between 7.5% and 10.0%) on stable oral antidiabetic therapy for at least 3 months. |
| Intervention | Once-weekly semaglutide (subcutaneous injection, 0.25 mg for 4 weeks, titrated up to 1.0 mg). |
| Comparison | Once-daily oral sitagliptin (100 mg) administered over a 52-week period. |
| Outcome | Semaglutide significantly improved lipid subfraction profiles, reduced total cholesterol, improved HbA1c levels (-1.8% vs. -0.9% with sitagliptin), and led to greater weight loss (-6.2 kg vs. -1.8 kg). Semaglutide was linked to mild gastrointestinal side effects such as nausea and diarrhea. |
Source: László Imre Tóth, et al. “Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study.” Read article here.
